Luteolin inhibits colorectal cancer cell epithelial-to-mesenchymal transition by suppressing CREB1 expression revealed by comparative proteomics study.
- Yuan Liu,
- Tingyuan Lang,
- Bingwei Jin,
- Feng Chen,
- Yi Zhang,
- Roger W Beuerman,
- Lei Zhou,
- Zhiqi Zhang
J Proteomics 2017 May 5;161:1-10. Epub 2017 Apr 5.
Shanghai University of Medicine & Health Sciences Shanghai Sixth People's Hospital East Campus, Shanghai 201306, PR China; Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China. Electronic address:
The cyclic AMP (cAMP) response element binding protein 1 (CREB1) is a promising target for cancer therapy. Here, we report that luteolin, a natural product, inhibits the expression of CREB1 at the transcriptional level and blocks epithelial-to-mesenchymal transition (EMT) of colorectal cancer cells. Treatment of colorectal cancer cells with luteolin induced mesenchymal-to-epithelial transition, reduced the expressions of mesenchymal markers and inhibited cell mobility in vitro. Read More